At what enterprise value was MATTON ORTHOMEDI acquired in 2025?

During the acquisition of MATTON ORTHOMEDI by OTTOBOCK in 2025, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 10M - 30M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of MATTON ORTHOMEDI when it was acquired by OTTOBOCK?

The exact EV/EBITDA multiple for MATTON ORTHOMEDI is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was MATTON ORTHOMEDI acquired by OTTOBOCK?

MATTON ORTHOMEDI was acquired by OTTOBOCK in 2025.

What was the revenue of MATTON ORTHOMEDI at the time of the deal?

The revenue of MATTON ORTHOMEDI at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the MATTON ORTHOMEDI acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the MATTON ORTHOMEDI deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.vigogroup.eu/fr/blog/vigo-en-orthomed-gaan-samen-verder-binnen-de-internationale-ottobock-groep

← DATABASE

Home Database Healthcare & PharmaMATTON ORTHOMEDI

05/2025

MATTON ORTHOMEDI acquired by OTTOBOCK

BELGIUM Life Sciences / Medical Devices / Implants & Prosthetics EV 10M - 30M EUR

Context

In May 2025, Ottobock, through its subsidiary Vigo, acquired Matton OrthoMedi as part of its strategy to consolidate the European technical orthopedics market. The primary objective of this acquisition is to strengthen Ottobock's network of care centers in Western Europe by integrating a well-established local player in Belgium. Matton OrthoMedi brings a established network of locations in Ghent, Bruges, and Brussels, as well as over 30 years of expertise in orthopedic care and custom device manufacturing, catering to patients with complex mobility needs. As part of this integration, Matton OrthoMedi will retain its operational identity and continue to operate autonomously, while leveraging Ottobock's industrial, clinical, and organizational resources. The goal is to optimize patient care pathways by enhancing coordination between local facilities and the group's treatment standards. Strategically, this acquisition enables Ottobock to accelerate its presence in the consolidating European orthopedics market, where value is shifting towards integrated networks that can combine patient proximity, practice standardization, and skill sharing. This deal is part of a platform strategy, aiming to aggregate specialized local players to build a more integrated, efficient, and patient-centric European orthopedic care network. By expanding its footprint in the region, Ottobock is poised to capitalize on the trend towards integrated care delivery, where providers can offer comprehensive and coordinated services to patients, ultimately driving better outcomes and improved patient satisfaction.

MATTON ORTHOMEDI, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Matton OrthoMedi is a leading Belgian player in the field of technical orthopedics and mobility solutions for patients. The company offers a comprehensive range of medical devices, including prosthetics, orthotics, orthopedic shoes, custom insoles, wheelchairs, and other mobility aids. With over 30 years of experience, Matton OrthoMedi has established itself as a trusted healthcare provider in Belgium, known for its patient-centric approach and extensive network of centers in Ghent, Bruges, and Brussels. The company employs approximately 68 specialized professionals who are dedicated to providing orthopedic care and functional rehabilitation. Its business model is built on strong technical expertise and the ability to deliver tailored solutions to complex medical needs, particularly in cases of reduced mobility. As a well-established player in the Belgian technical orthopedics market, Matton OrthoMedi enjoys significant local recognition. Following its integration into the Vigo network and subsequently the Ottobock group, the company has become part of a broader European platform, while maintaining its local roots and close relationships with patients.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
07/2025	BC PARTNERS	BIOGARAN	FRANCE	Life Sciences	BC Partners, a leading European investment firm, and Bpifrance have finalized the landmark acquisition of Biogaran from Servier. As a cornerstone of the French pharmaceutical industry and the domestic leader in generic medicines, Biogaran enters a new phase of independence
07/2025	PATRICIA INDUSTRIES	NOVA BIOMEDICAL	UNITED STATES	Life Sciences	Advanced Instruments has finalized the acquisition of Nova Biomedical, a maneuver designed to fundamentally reshape the global biopharma analytics and clinical diagnostic landscape. The strategic rationale for this transaction centers on a "portfolio-convergence" play, merging the target's industry-leading point-of-care and bioprocess monitoring technology with the group’s established leadership in osmometry and specialized lab analytics
05/2025	IK PARTNERS	BIOBANK	FRANCE	Life Sciences	This transaction structurally constitutes a tertiary leveraged buyout, marking a significant reorganization of the target's capital structure. The incoming pan-European financial sponsor successfully preempted a highly competitive auction process orchestrated by a specialized investment bank, decisively securing a majority controlling stake
04/2025	IK PARTNERS	STERIMED	FRANCE	Life Sciences	Sterimed completes its third buy-out (LBO) as IK Partners returns as the majority shareholder, taking over from Sagard. This transaction values the group at over EUR1 billion, a significant jump from its previous valuation
04/2025	PATIENT SQUARE CAPITAL	PATTERSON COMPANIES	UNITED STATES	Life Sciences	Patient Square Capital completed the acquisition of 100% of Patterson Companies, taking the business private and delisting it from the NASDAQ Global Select Market. Patterson will maintain its headquarters in St
04/2025	CINVEN	NUTRISENS	FRANCE	Life Sciences	Cinven acquires a majority stake in the French clinical nutrition group Nutrisens from Sagard. The transaction values the company at over EUR700 million. Under Sagard's tenure, Nutrisens tripled its size through organic growth and acquisitions
04/2025	NORGINE	THERAVIA	FRANCE	Life Sciences	Private equity firm Mérieux Equity Partners has entered into a definitive agreement to divest its controlling equity stake in the pharmaceutical laboratory Theravia to the Dutch group Norgine, a portfolio company backed by Goldman Sachs Asset Management
04/2025	INSTITUT MERIEUX / ARCHIMED	CEVA SANTE ANIMALE	FRANCE	Life Sciences	Ceva organized its sixth LBO to support its continued growth. The transaction values the group at over EUR9 billion (nearly double the EUR5bn valuation in 2020). Two new shareholders joined the table: Institut Merieux (strengthening the existing presence of Merieux Equity Partners) and Archimed (investing via its large-cap fund)
03/2025	ZYDUS	AMPLITUDE SURGICAL	FRANCE	Life Sciences	Zydus entered into exclusive negotiations to acquire a controlling 85.6% stake (block trade) in Amplitude Surgical from PAI Partners, the management and minority shareholders. The offer price is EUR6.25 per share, representing an 80
03/2025	NUTRISENS	PRODIET	BRAZIL	Life Sciences	Nutrisens Group has acquired a majority stake in Prodiet Medical Nutrition, a Brazilian leader in clinical nutrition. The founders of Prodiet, Armando Tortelli and Ana Paula Celes, retain a minority stake and will continue to support the company's growth, while Gabriel Tortelli remains as CEO

REFERENCES

Valuation range: EV 10M - 30M EUR

Revenue range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of MATTON ORTHOMEDI by OTTOBOCK are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: matton orthomedi

Acquirer: ottobock